Binance Labs invests in BIO Protocol to revolutionize decentralized science

Source Cryptopolitan

Binance Labs, the crypto exchange’s venture capital arm, has invested in decentralized science (DeSci) by backing the BIO Protocol. This accelerator is designed to help early-stage scientific research startups access decentralized funding opportunities.

BIO Protocol expands its BioDAO network

BIO Protocol promotes a network of Biotech Decentralized Autonomous Organizations (BioDAOs), which form communities to fund, develop, and co-own innovative pharmaceuticals and therapies. According to Binance Labs, BioDAOs solve gaps in traditional funding for rare diseases, longevity research, and emergent health concerns.

The details of the investment’s exact amount were not disclosed, but it will enable BIO Protocol to grow its network by providing seed funding for new projects and strengthening community and tokenomics support. Binance Labs’ Investment Director Andy Chang commented:

“BIO Protocol represents a significant step forward in DeSci by merging biotechnology and DeFi. At Binance Labs, we are dedicated to unlocking groundbreaking advancements that drive long-term, real-world impact by supporting projects building meaningful technology.”

~Andy Chang

Binance Labs has more than 200 projects in its portfolio, most of which contribute to the development of decentralized finance. However, some involve gaming, artificial intelligence, and other sectors. For instance, Binance Labs supports Pluto Studio, which established the popular tap-to-earn Telegram mini-app Catizen.

Binance Labs and BIO Protocol to support IP-driven DAOs

BIO Protocol’s network of eight BioDAOs had a market capitalization of $200 million in November 2023. As co-founder of the Molecule platform, BIO Protocol’s Paul Kohlhaas introduced intellectual property non-fungible tokens (IP-NFTs). The protocol supports the sale of IP-NFTs.

One of BIO Protocol’s cornerstone projects, longevity-focused VitaDAO, was founded in 2021. In February 2023, it obtained $4.1 million in funding from pharmaceutical manufacturer Pfizer and supported the launch of Matrix Biosciences in October.

According to Binance Labs, the protocol’s next batch will feature projects to find a cure for Long COVID and rare diseases and build quantum microscopes to examine quantum biological processes.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
【Daily Brief】10-year Treasury yield briefly tops 5%, S&P 500 slips to 7,602 and the dollar firms at 99.3 as the Fed's decision eve beginsThe 10-year Treasury yield touched 5.014% on Monday — its first print above 5% since October 2023 — while the S&P 500 closed 0.48% lower at 7,619.98 and the dollar index firmed to 99.3. Here is the full market wrap ahead of Wednesday's FOMC decision, the dot plot and the August retail sales report, plus today's CLARITY Act Senate vote.
Author  Irene Q.
Sep 15, Tue
The 10-year Treasury yield touched 5.014% on Monday — its first print above 5% since October 2023 — while the S&P 500 closed 0.48% lower at 7,619.98 and the dollar index firmed to 99.3. Here is the full market wrap ahead of Wednesday's FOMC decision, the dot plot and the August retail sales report, plus today's CLARITY Act Senate vote.
placeholder
October hike odds climb toward 60% as Goldman and BofA both flip — what Warsh's "dose of accommodation" really changedRate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.
Author  Irene Q.
Sep 23, Wed
Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.
placeholder
Gold holds steady below $4,150 amid elevated US yields Gold price (XAU/USD) trades on a flat note near $4,140 during the early Asian session on Tuesday. Pressure from a stronger US Dollar (USD) and elevated US Treasury yields was offset by reduced expectations of a Federal Reserve (Fed) rate hike this month.
Author  FXStreet
Yesterday 01: 14
Gold price (XAU/USD) trades on a flat note near $4,140 during the early Asian session on Tuesday. Pressure from a stronger US Dollar (USD) and elevated US Treasury yields was offset by reduced expectations of a Federal Reserve (Fed) rate hike this month.
placeholder
Japanese Yen drifts lower as sustained USD buying offsets intervention fearsThe USD/JPY pair attracts some buyers following the previous day's two-day price moves, trading above the 158.00 mark during the early part of the European session on Tuesday.
Author  FXStreet
18 hours ago
The USD/JPY pair attracts some buyers following the previous day's two-day price moves, trading above the 158.00 mark during the early part of the European session on Tuesday.
placeholder
AUD/USD Price Forecast: Struggles to return to 0.7000 amid firm US DollarThe Australian Dollar (AUD) gives back its early gains after rising to near 0.6975 and turns marginally lower at around 0.6964 against the US Dollar (USD) during the European trading session on Tuesday.
Author  FXStreet
17 hours ago
The Australian Dollar (AUD) gives back its early gains after rising to near 0.6975 and turns marginally lower at around 0.6964 against the US Dollar (USD) during the European trading session on Tuesday.
goTop
quote